PhysioLogic Devices’ management team represents decades of professional and personal experience in all aspects of Type 1 Diabetes.
Greg Peterson, CEO
Greg is a successful hardware and software development entrepreneur who has lived with Type 1 diabetes since 1957. In 1992, after 35 years of managing his diabetes with subcutaneous insulin, Greg received his first implantable insulin pump, developed by Pete Lord. The immediately apparent and dramatic life-changing benefits of near-physiologic intraperitoneal insulin delivery motivated him to dedicate his efforts to ensuring that all who live with the challenges of T1D have access to this extraordinarily liberating and life-altering technology. In 2007, when the only available implantable insulin pump was discontinued in the United States, Greg led a small group of fellow patients to Montpellier, France and Professor Eric Renard, a world-renowned leader in implantable insulin pump therapy. Twelve years later, these patients continue to travel to France every three months to preserve their implantable insulin pumps and to support efforts to bring this technology to all those who live with T1D. Greg has senior authored multiple diabetes related research articles in leading medical journals.
Peter Lord, Chief Technology Officer and Founder
Pete has dedicated his entire engineering career to the development of progressively more sophisticated external and implantable insulin pumps. He was the lead engineer for the development of a series of implantable insulin pumps, beginning with the PIMS (Programmable Implantable Medication System) series and continuing through to the MIP 2001 (MiniMed Implantable Pump) series and ultimately the MIP 2007D, the only existing implantable insulin pump, which has benefitted hundreds of devoted patients. Pete is widely recognized as a world leader in the development of implantable medical devices. His stellar reputation in the field has allowed PhysioLogic Devices to attract a team of engineers with rare decades-long experience in the development of implantable insulin pumps. Pete has successfully headed regulatory, research and development and clinical research teams throughout his career. His dedication to improving the lives of those living with Type 1 diabetes inspired him to found PhysioLogic Devices, with the aim of creating the first truly autonomous blood glucose management system.
Jennifer Schneider, MD, Chief Medical Officer, Chief Operating Officer
Jennifer is a highly respected Stanford trained physician-scientist. Her early career focus was on orthopedic surgery with a subspecialty in surgery of the hand, leading her to establish the Division of Hand Surgery for the Palo Alto Medical Foundation. In 2003, in the midst of a rapidly accelerating surgical career, Jennifer was abruptly introduced to the world of Type 1 diabetes when her two-year old daughter was diagnosed with T1D. Few who have not directly experienced the daunting physical and emotional challenges of caring for such a young child with Type 1 diabetes can understand how it can consume one’s life. In Jennifer’s case, it altered the course of her career. Her early interest in translational medicine led Jennifer to found a diabetes device company that successfully exited to Insulet Corporation. She currently serves on the International Board of Directors for JDRF (Juvenile Diabetes Research Foundation), on the Scientific Advisory Board for Beyond Type 1, and she is a visiting scholar at Stanford University. Jennifer earned her undergraduate degree from Harvard University and her medical degree from Georgetown University. She has a number of published scientific papers, and we are indeed privileged to have her on our team.
Gerda Resch, Director of Regulatory Affairs and Quality Assurance
Gerda’s extensive experience in regulatory affairs, with an emphasis on medical devices in both Europe and the United States, provides PhysioLogic Devices with the critical capability to successfully navigate this complex arena. Gerda has worked with Medtronic, Baxter, Ioptex, Alfred Mann Foundation and MiniMed, and has extensive experience in quality control, microbiology, OTC drug regulation and process improvement. Gerda has been certified as an ISO 9001 assessor, an ASQ quality auditor, biomedical auditor and in-house auditor. Her responsibilities have included internal auditing, quality systems, international and domestic medical devices, biologics and combination product submissions, CE marking, risk management, regulatory compliance, handling complaints, labeling and import-export. In the field of distribution support, she has held the position of authorized designated pharmacy representative, with verified authorized wholesale distributor oversight (National Association of Boards of Pharmacy) and distribution licensing. Gerda’s experience with the implantable insulin pump began in the 1990s with the introduction of the model MIP 2001 in the United States and Europe.
Daniel Merrill, PhD, Chief Science Officer
Dan’s career has spanned academic, nonprofit, and for-profit sectors of medical device development for over 30 years. He was diagnosed with Type 1 diabetes at the age of 4 and has long been a supporter of the development and expanded availability of the implantable insulin pump. His early career in industry was followed by a return to academia and postdoctoral work, including research in the area of tissue response to chronically implanted devices – experience critically important to the development of an implanted insulin pump. His research experience also includes the application of implantable sensors and a successful track record for research grant writing and review. Most recently, he headed the assembly and coordination of an international cooperative resulting in the submission of a significant grant request to a major European scientific agency. Dan was also the project manager for a multi-year effort to explore applying state-of-the-art technology to the development of an advanced implantable insulin pump – experience directly applicable to advancing the goals of PhysioLogic Devices. His publications have become standard training material among biomedical engineering
Dana Fenwick, Chief Financial Officer
Dana’s expertise in leveraged finance, financial analysis and risk management has benefited both nonprofit and for-profit organizations and their constituencies for over three decades. Dana began her career in finance at Citibank in New York soon after graduating from Princeton University. From there she moved to Wells Fargo in San Francisco and subsequently to Union Bank where, as Vice President, she managed a loan portfolio in excess of $100 million. Deploying her expertise from a successful career in commercial banking, Dana moved into leadership roles as treasurer and board member for numerous nonprofit organizations. Dana continues her leadership roles in mission driven organizations, and is currently serving on the Human Rights Watch Silicon Valley Executive Committee and the Board of Directors for Pursuit of Excellence Scholarships. Dana joined PhysioLogic Devices as CFO, merging her banking and treasury expertise with her passion for mission driven organizations. Dana’s connection with T1D is personal. Her close friend has lived with T1D for over 30 years.